Biotech News
-
Valeo Pharma Obtains Public Reimbursement for Enerzair® Breezhaler® and Atectura® Breezhaler® in Quebec and Nova Scotia
Public reimbursement now includes Alberta, Quebec and Nova Scotia, representing approximately 37% of the Canadian population. More than…
-
XPhyto Epilepsy clinical trial planned in 2022 with its proprietary fast-dissolving CBD oral strips
December 15, 2021 (Source) — XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is…
-
Sixth Wave AMIPs(TM) Demonstrate Virus Detection in Saliva Samples
December 14, 2021 (Source) — Sixth Wave Innovations Inc. (CSE: SIXW) (OTCQB: SIXWF) (FSE: AHUH) (“Sixth Wave”, “SIXW” or…
-
Awakn Life Sciences Appoints Former EVP & Chief Commercial Officer of Gilead Sciences, Paul Carter, as Independent Member of its Board of Directors
December 14, 2021 (Source) — Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company…
-
Sixth Wave Readies to Commercialize Technology for Fast, Accurate, and Inexpensive Covid-19 Tests
December 13, 2021 (Source) — Building on its revolutionary approach to detecting the virus that causes Covid-19, Sixth Wave…
-
Valeo Pharma Closes Previously Announced Upsized $15 Million Bought Deal Private Placement and Concurrent $10 Million Private Placement from Investissement Quebec
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. FAILURE TO COMPLY…
-
Hemostemix Announces Soft Lock of Database as Source Document Verification Completed
December 9, 2021 (Source) — Hemostemix Inc. (TSXV: HEM) (OTCQB :HMTXF) (FSE: 2VFO) (“Hemostemix” or the “Company”) is pleased…
-
Element Nutritional Sciences Receives DTC Eligibility
December 8, 2021 (Source) — Element Nutritional Sciences Inc. (CSE:ELMT; OTC:ELNSF; FRANKFURT:93X) (the “Company” or “Element”), is pleased…
-
Voyageur Pharmaceuticals Provides Update on PEA Progress & Takes a Major Step Towards Production Start Up
December 6, 2021 (Source) — Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the “Company” or “Voyageur”) has a preliminary economic assessment (PEA) on its Frances…
-
XPhyto Completes Strategic Acquisition of 3a-diagnostics GmbH
The acquisition positions XPhyto to be a leading Biosensor producer integrating thin film technology with 3a-diagnostics biosensor technology…
